SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak Co. is trending due to its ongoing transformation from a legacy print business into high-margin sectors like pharmaceuticals and advanced materials, with the community highlighting the imminent launch of its pharma division in 2025. Discussions also focus on the company's debt reduction plans using pension assets, potential trade policy tailwinds, and undervalued real estate holdings. Investors are closely watching for news and contracts related to Kodak's pharmaceutical ventures, with some speculating about partnerships and a potential meme stock resurgence.

The Filecoin network achieves staggering economies of scale by allowing anyone worldwide to participate as storage providers. It also makes storage resemble a commodity or utility by decoupling hard-drive space from additional services. On this robust global market the price of storage will be driven by supply and demand, not corporate pricing departments, and miners will compete on factors like reputation for reliability as well as price.

Filecoin

Filecoin is trending as investors discuss its potential in decentralized data storage, especially in light of AI and Web3 projects. Community members are actively comparing it to other cryptocurrencies like ZEC and DASH, speculating on price targets, and highlighting its real-world utility, such as competing with Amazon AWS. The conversation also mentions Filecoin's use cases with Solana and NASA.

P8BCI Is the CCM Creator Capital Markets Creator token created by Nick Wray, intended to form a community for talking about his journey with ALS, his experiences with Telepathy BCI experiments, as well as his experiences and journey through the Solana blockchain, and cryptocurrency world of Web 3. In addition to this, prior to his progression of ALS Nick was an avid drummer, a creative, and an enjoyer of philosophical discussion - and enabled now by his BCI explores creating, and in addition to sharing his story, interacting with the community forming around his experiences.

Telepath8

Telepath8 ($P8BCI) is trending amid community excitement over its developer's purported connection to Neuralink and Elon Musk. Discussions center on the project's innovative development process and potential synergies with neurotechnology, fueling bullish sentiment.

Crane Harbor Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 2, 2025 and is headquartered in Philadelphia, PA.

Crane Harbor Acquisition Corp. - Ordinary Shares - Class A

Chardan Healthcare

Chardan Healthcare (CHAC) is trending due to its merger with Xanadu, a quantum computing firm, generating excitement within the community. Discussions revolve around Xanadu's technology, including its PennyLane software and potential partnerships, as well as comparisons to other quantum computing companies. Some are also looking into CHAC's rights offerings and their relationship to the stock.

COTI is a fast and light confidentiality layer on Ethereum. Powered by the breakthrough cryptographic protocol Garbled Circuits and secured by Ethereum, COTI introduces the most advanced and compliant solution for data protection on the public blockchain. Paving the way for the next wave of Web3 innovation and adoption, COTI unlocks a whole new world of use cases, including confidential transactions, Artificial Intelligence, DeFi, decentralized identification, and more.

COTI

COTI is trending as the community discusses its potential in the privacy and security sector, with comparisons being made to established coins like ZEC and its growing ecosystem. Bullish sentiment seems to be building, with some anticipating mainnet and new partnerships to serve as catalysts. Community members are also talking about accumulation and COTI's AI-driven trading potential.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant is seeing increased attention, with community members discussing its potential for significant gains and comparing it to other cryptocurrencies. Recent news and partnerships are fueling optimism, though some traders remain skeptical, pointing to past performance. Overall, the community is weighing the long-term potential of Quant against short-term market fluctuations.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy ($CHWY) is trending as traders discuss its upcoming earnings and potential breakout, with some highlighting Mizuho's recent upgrade and a price target of $50. Bullish sentiment seems to be building due to strong Autoship sales and recurring revenue, even amid discussions of competition and market volatility. Some are speculating on a run to the $40-$50 range, while others are wary, citing past earnings disappointments and broader market concerns.

Sei is a high-performance Layer 1 blockchain that scales the EVM with parallelized execution, enabling faster transactions, low fees, and seamless smart contract deployment. Sei removes traditional blockchain bottlenecks while maintaining full Ethereum compatibility. The upcoming Giga upgrade will deliver 50x improvements in EVM throughput, optimizing execution, consensus, and storage to push blockchain performance to web2 levels.

SEI is gaining attention as community members discuss its potential, comparing it to other popular chains like Solana and SUI. The recent listing on Robinhood is a catalyst, with some seeing it as a signal for potential growth, while others express concern about its historical impact on coin performance. Community discussions include speculation on future price targets and debate around whether it's a good entry point.

Ambiq Micro, Inc. engages in the provision of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI computing. It operates through the following geographical segments: China, Taiwan, Singapore, and Rest of the World. The company was founded by Scott Hanson, Dennis Sylvester, and David Blaauw on January 20, 2010 and is headquartered in Austin, TX.

Ambiq Micro Inc.

Ambiq Micro, Inc.

Ambiq Micro ($AMBQ) is trending as the community discusses its potential in the AI chip space, particularly its focus on ultra-low power solutions and key partnerships. Despite recent earnings, sentiment is mixed, with some expressing frustration and others hoping for a buyout or strategic move to unlock value. Bullish investors point to the company's innovative technology and potential for significant growth in the edge AI market, drawing comparisons to other successful chip companies.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA is trending amidst discussions about its recent earnings report and future prospects, with community members debating its valuation and potential for growth. Despite some disappointment in immediate stock reaction, optimism persists around long-term potential, including revenue projections and potential buybacks. The company's fundamentals and possible acquisition are also being actively discussed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK Buys Global Rights To Preclinical Cancer Therapy For $357M

In preclinical studies, the ADC was effective at shrinking tumors without causing a proportional increase in significant side effects, even at higher doses, GSK said. 

Equity

The National Highway Traffic Safety Administration (NHTSA) announced on Monday that it has closed its investigation into approximately 24,000 model year 2017-2018 Alfa Romeo Giulia vehicles.The U.S. auto safety regulator’s Office of Defects Investigation (ODI) had opened the probe in January 2024 to assess allegations of loss of motive power resulting from low-pressure fuel pump failures in certain Alfa Romeo Giulia vehicles. During its investigation, the NHTSA <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/inv/2024/INCLA-PE24003-86036.pdf">determined</a> that the vehicles were equipped with fuel delivery pumps supplied by Vitesco Technologies Germany GmbH.However, Stellantis issued a recall earlier this month covering 29,467 model-year 2017–2019 Alfa Romeo Giulia vehicles and 24,382 model-year 2018 Alfa Romeo Stelvio vehicles, all equipped with the suspect Vitesco fuel delivery pump. A remedy is under development, the company said.The NHTSA stated that it is closing its probe in light of the recall issued by Stellantis. However, the regulator said it reserves the right to take additional action if warranted.The NHTSA also noted that it is aware of 1,900 vehicles experiencing failures related to the issue, adding that it is aware of one crash associated with the issue, but no injuries, fatalities, or fires.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/STLA">STLA stock</a> remained within ‘bearish’ territory while message volume remained at ‘high’ levels.The NHTSA also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/inv/2024/INCLA-PE24006-86034.pdf">announced </a>on Monday that it has closed a probe into 226,250 model year 2018-2020 Dodge Journey vehicles, which was initiated in February 2024 due to complaints regarding the backup camera function. The company recently issued a recall to resolve the issue and noted that it will replace defective cameras in the recalled vehicles with an updated part that resolves the problem.STLA stock is down 29% this year and approximately 34% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A new Alfa Romeo Giulia on display at the Edmonton Motor Show on April 13, 2025, in Edmonton, Alberta, Canada. (Photo by Artur Widak/NurPhoto via Getty Images)

US Regulator Closes Probe Into Stellantis’ 24,000 Alfa Romeo Giulia Vehicles

The U.S. auto safety regulator’s Office of Defects Investigation (ODI) had opened the probe in January 2024 to assess allegations of loss of motive power resulting from low-pressure fuel pump failures. 

Shares of Swiss pharmaceutical giant Novartis AG were flat on Friday morning in heavy trading volume, despite the company reporting impressive quarterly results.&nbsp;Novartis posted core fourth-quarter (Q4) earnings per share (EPS) of $1.98, up from $1.53 last year, beating the consensus estimate of $1.80.&nbsp;Meanwhile, Q4 revenue reached $13.2 billion, surpassing the previous year’s $11.4 billion and analysts’ expectations of $12.84 billion.The company attributed its strong sales growth to its blockbuster heart-failure drug Entresto and arthritis medication Cosentyx.&nbsp;CEO Vas Narasimhan expressed optimism, stating, “In our first full year as a pure-play innovative medicines company, Novartis delivered one of the strongest financial performances in our history, growing sales 12% cc [constant currency basis] and core operating income 22% cc.”&nbsp;He added that the company achieved key innovation milestones, including new drug approvals and promising data that would drive growth in the mid- to long-term.Despite the upbeat results, retail sentiment on Stocktwits was mixed. Although message volume surged into ‘extremely bullish’ territory, sentiment remained ‘bearish,’ indicating some hesitation among retail traders.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/NVS_sentiment_and_message_volume_Jan_31_d92ad15174.png" alt="NVS sentiment and message volume Jan 31.png" width="1318" height="324"><figcaption>NVS sentiment and message volume Jan 31 as of 11:45 am ET | source: Stocktwits</figcaption></figure>Novartis is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year.&nbsp;Additionally, two other top-selling drugs, Tasigna for leukemia and Promacta for a blood disorder, will face generics in the U.S.However, Narasimhan reassured investors, emphasizing the company’s “tremendous replacement power” and its ability to bring new treatments to market when patents on existing drugs expire.&nbsp;He also highlighted the company’s strong pipeline, with more than 30 assets that could drive differentiated growth over the long term, including updates on its cardiovascular drug candidate pelacarsen and a key late-stage trial this year.Looking ahead, Novartis forecasted FY25 net sales growth in the mid- to high-single-digit range, with core operating income expected to grow in the high single to low double-digit range.&nbsp;The company also proposed a 6.1% increase in its dividend to 3.50 Swiss francs per share for 2024.Although <a href="https://stocktwits.com/symbol/NVS">Novartis' stock</a> has lost 0.1% over the past 12 months, it is up more than 7% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading

The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year. 

EA Series Trust - Altrius Global Dividend ETF

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

DIVD
EA Series Trust - Altrius Global Dividend ETF

Feed

News

Sentiment

Fundamentals

Info

Latest DIVD News

DIVDEA Series Trust - Altrius Global Dividend ETF